DnB Asset Management AS Increases Stock Holdings in Teva Pharmaceutical Industries Limited (NYSE:TEVA)

DnB Asset Management AS boosted its stake in Teva Pharmaceutical Industries Limited (NYSE:TEVA - Free Report) by 13.3% in the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 184,940 shares of the company's stock after purchasing an additional 21,727 shares during the quarter. DnB Asset Management AS's holdings in Teva Pharmaceutical Industries were worth $4,076,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also bought and sold shares of the company. Intech Investment Management LLC acquired a new stake in Teva Pharmaceutical Industries in the third quarter valued at about $439,000. Charles Schwab Investment Management Inc. increased its position in Teva Pharmaceutical Industries by 24.7% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 899,175 shares of the company's stock worth $16,203,000 after purchasing an additional 177,836 shares in the last quarter. The Manufacturers Life Insurance Company lifted its stake in Teva Pharmaceutical Industries by 5.9% in the 3rd quarter. The Manufacturers Life Insurance Company now owns 432,402 shares of the company's stock valued at $7,792,000 after purchasing an additional 24,248 shares during the last quarter. Townsquare Capital LLC acquired a new stake in Teva Pharmaceutical Industries in the third quarter valued at approximately $709,000. Finally, Bridgewater Associates LP boosted its position in Teva Pharmaceutical Industries by 5.2% in the third quarter. Bridgewater Associates LP now owns 23,222 shares of the company's stock valued at $418,000 after buying an additional 1,144 shares in the last quarter. Institutional investors own 54.05% of the company's stock.

Remove Ads

Teva Pharmaceutical Industries Stock Down 8.4 %

Shares of NYSE TEVA traded down $1.25 during midday trading on Friday, hitting $13.61. 11,979,372 shares of the stock traded hands, compared to its average volume of 12,190,776. Teva Pharmaceutical Industries Limited has a one year low of $12.51 and a one year high of $22.80. The company has a market cap of $15.43 billion, a PE ratio of -9.37, a P/E/G ratio of 1.44 and a beta of 0.82. The company has a debt-to-equity ratio of 2.97, a quick ratio of 0.75 and a current ratio of 0.98. The business has a 50 day moving average price of $16.67 and a two-hundred day moving average price of $18.04.

Teva Pharmaceutical Industries (NYSE:TEVA - Get Free Report) last announced its quarterly earnings data on Wednesday, January 29th. The company reported $0.70 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.69 by $0.01. Teva Pharmaceutical Industries had a positive return on equity of 42.46% and a negative net margin of 9.91%. On average, equities analysts predict that Teva Pharmaceutical Industries Limited will post 2.5 EPS for the current year.

Wall Street Analysts Forecast Growth

TEVA has been the subject of several analyst reports. UBS Group lowered their target price on Teva Pharmaceutical Industries from $30.00 to $27.00 and set a "buy" rating for the company in a research report on Thursday, January 30th. Bank of America dropped their price target on shares of Teva Pharmaceutical Industries from $23.00 to $20.00 and set a "buy" rating on the stock in a research report on Thursday, March 6th. Piper Sandler increased their price objective on shares of Teva Pharmaceutical Industries from $23.00 to $30.00 and gave the stock an "overweight" rating in a research report on Friday, January 17th. Barclays dropped their target price on shares of Teva Pharmaceutical Industries from $28.00 to $26.00 and set an "overweight" rating on the stock in a report on Thursday, January 30th. Finally, StockNews.com raised Teva Pharmaceutical Industries from a "hold" rating to a "buy" rating in a research report on Friday. One research analyst has rated the stock with a hold rating and seven have issued a buy rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and a consensus target price of $23.43.

Teva Pharmaceutical Industries Profile

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.